Novavax: Health Canada Approves Nuvaxovid COVID-19 Vaccine As Adult Booster

Novavax, Inc. (NVAX) announced that Health Canada has granted expanded authorization for Nuvaxovid for active immunization to prevent coronavirus disease 2019 caused by SARS-CoV-2 as a homologous booster in adults aged 18 and older. The company said the expanded authorization was based on data from a phase 2 trial conducted in South Africa and from the Prevent-19 phase 3 trial conducted in the U.S. and Mexico.

Health Canada previously authorized Nuvaxovid as a primary series in adults aged 18 and older in February 2022.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Comcast Corp. on Thursday reported that profit for the fourth quarter edged down 1.1 percent from last year, reflecting higher costs and expenses. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a 7.4 percent higher quarterly dividend. Shares of SAP AG were losing more than 3 percent in the morning trading in Germany as well as in pre-market activity on the NYSE after the German software major reported Thursday sharply lower profit in its fourth quarter, despite higher revenues. Looking ahead for fiscal 2023, the company projects accelerating topline and double-digit adjusted operating profit growth. Meta Platforms announced its plans to end suspension of the former U.S. President Donald Trump's Facebook and Instagram accounts in the coming weeks. Further, the company has put new guardrails in place to deter repeat offenses, Global Affairs President Nick Clegg said in a statement. The decision comes after two years of banning him on the social media platforms following his praise for people...
Follow RTT